NCT07459062 (SPCTR-I) is a clinical trial in Margin Assessment, sponsored by SPCTR.

Who is sponsoring NCT07459062?

NCT07459062 is sponsored by SPCTR.

What condition does NCT07459062 study?

NCT07459062 studies Margin Assessment, Breast Cancer.

Is NCT07459062 still recruiting?

NCT07459062 is currently recruiting now. Last updated 9 March 2026.

Last reviewed 2026-03-09 · How we verify

NCT07459062: SPCTR-I

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Spectral Cancer Tissue Recognition - I

Recruiting now Last updated 9 March 2026

What this trial tests

trial in Margin Assessment in 100 participants. Currently enrolling.

Timeline

12 January 2026

Primary endpoint
1 August 2026

1 August 2026

Quick facts

Lead sponsor	SPCTR
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	100
Start date	12 January 2026
Primary completion	1 August 2026
Estimated completion	1 August 2026
Sites	2 locations across Netherlands

Conditions studied

Margin Assessment — all drugs for Margin Assessment →
Breast Cancer — all drugs for Breast Cancer →

Sponsor

SPCTR — full company profile →

Who can join

18 and older, any sex, with Margin Assessment or Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This analytical performance study aims to validate the SPCTRone system for use in breast conserving surgery of breast cancer patients. By collecting spectral biomarkers and correlating these with the golden standard of histopathological assessment by a pathologist, we aim to train and optimize an AI model that is able to achieve the following outcomes with classifying tissues: * Sensitivity (percentage of classified positive margins of actual positive margins): ≥ 96% CI 95.5-97.5% * Specificity (percentage of classified free margins of actual free margins): 96% CI 95.5-97.5% * Accuracy (total correctly classified margins): ≥ 96% CI 95.5-97.5% * Negative predictive value (amount of true negative - free margins - among the classified negative margins): ≥ 95% CI 94.5-96.5%

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Margin Assessment

Currently open trials in the same condition.

NCT07149207 — Intraoperative Molecular Imaging Using ICG for Head and Neck Tumors · Phase 2 · recruiting
NCT06713161 — Tumor-Targeted-NIR-II Fluorescent Molecular Probes for the Identification of Breast Cancer Tissue and SLN Metastatic Sta · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07459062 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by SPCTR
Last refreshed: 9 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07459062.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing